Emsam Transdermal and Lorbrena
Determining the interaction of Emsam Transdermal and Lorbrena and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration with lorlatinib may decrease the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 2B6. The proposed mechanism, based on in vitro data, is increased clearance due to lorlatinib-mediated induction of CYP450 2B6. MANAGEMENT: Caution is recommended if lorlatinib is used concomitantly with drugs that are substrates of CYP450 2B6, particularly those with a narrow therapeutic range. The potential for diminished therapeutic effects should be considered when lorlatinib is prescribed in combination with drugs that are CYP450 2B6 substrates. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever lorlatinib is added to or withdrawn from therapy with these drugs. An alternative agent with no or minimal CYP450 2B6-inducing activity may also be considered. References Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Professional:MONITOR: Coadministration with lorlatinib may decrease the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 2B6. The proposed mechanism, based on in vitro data, is increased clearance due to lorlatinib-mediated induction of CYP450 2B6.
MANAGEMENT: Caution is recommended if lorlatinib is used concomitantly with drugs that are substrates of CYP450 2B6, particularly those with a narrow therapeutic range. The potential for diminished therapeutic effects should be considered when lorlatinib is prescribed in combination with drugs that are CYP450 2B6 substrates. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever lorlatinib is added to or withdrawn from therapy with these drugs. An alternative agent with no or minimal CYP450 2B6-inducing activity may also be considered.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Generic Name: selegiline
Brand name: Emsam, Eldepryl, Zelapar
Synonyms: Emsam
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Emsam Transdermal-Lorcaserin
- Emsam Transdermal-Lorcaserin Extended-Release Tablets
- Emsam Transdermal-Lorcaserin Hydrochloride
- Emsam Transdermal-Lorcaserin Tablets
- Emsam Transdermal-Lorcet
- Emsam Transdermal-Lorcet Plus
- Lorbrena-Emtricitabine
- Lorbrena-Emtricitabine and tenofovir
- Lorbrena-Emtricitabine and Tenofovir Alafenamide
- Lorbrena-Emtricitabine and Tenofovir Disoproxil Fumarate
- Lorbrena-Emtricitabine and Tenofovir Tablets
- Lorbrena-Emtricitabine Capsules